Patents Examined by Jean C. Witz
  • Patent number: 8703716
    Abstract: The invention provides methods and compositions for improving fetal and child health and development through nutritional supplementation with, for example, sialic acid. Sialic acid can be provided to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child. The sialic acid can be in a variety of forms in the supplements.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: April 22, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: John P. Zimmer, Christopher M. Butt
  • Patent number: 8680045
    Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: March 25, 2014
    Assignee: PeptiMed, Inc.
    Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
  • Patent number: 8673849
    Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antiviral activity, particularly against integrin-using viruses, more particularly against rotavirus. Further, the present invention refers to compositions comprising said peptidic compounds for medical use or for use as food additives.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: March 18, 2014
    Assignee: ROTALACTIS Srl
    Inventors: Amedeo Conti, David Lembo, Claudio Fabris, Enrico Bertino, Santo Landolfo
  • Patent number: 8673847
    Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: March 18, 2014
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, Jr.
  • Patent number: 8623377
    Abstract: The present invention provides peptides that home to a joint of an animal, wherein said peptide comprises an amino acid motif selected from the group consisting of NQR and ADK. Also provided are methods of treating a subject having an arthritic joint, comprising the step of administering to said subject a pharmacologically effective dose of a composition provided herein.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: January 7, 2014
    Assignee: University of Maryland, Baltimore
    Inventors: Kamal Moudgil, Ying-hua Yang
  • Patent number: 8580852
    Abstract: The disclosure provides a series of 2-oxoamides based on dipeptides and pseudodipeptides, which were synthesized and their activities toward two human intracellular phospholipases A2 (GIVA CPLA 2 and GVIA 1PLA 2) and one human secretory phospholipase A2 (GV sPLA 2) were evaluated. Derivatives containing a free carboxyl group are selective GIVA cPLA 2 inhibitors. A derivative based on the ethyl ester of an ether pseudodipeptide is the first 2-oxoamide, which preferentially inhibits GVIA iPLA 2. The effect of 2-oxoamides on the generation of arachidonic acid from RAW 264.7 macrophages was also studied. It was found that selective GIVA cPLA 2 inhibitors preferentially inhibited cellular arachidonic acid release; in which one pseudodipeptide gave an IC50 value of 2 ?M.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: November 12, 2013
    Assignee: The Regents of the University of California
    Inventors: Edward A. Dennis, George Kokotos, Violetta Constantinou-Kokotou
  • Patent number: 8557771
    Abstract: Provided is a homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof, wherein the insulinotropic peptide analogue comprises GLP-1 and Exendin-4. The homodimer of insulinotropic peptide analogues of the invention is made by conjugating two identical insulinotropic peptide analogue molecules at the C-terminal Cys residues via disulfide bond or PEG molecule. The homodimer of insulinotropic peptide analogues of the invention has superior stability and biological activity in vivo, and prolonged half-life in the circulation, and can be used for the preparation of hypoglycemic drugs.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: October 15, 2013
    Assignee: Chongqing Fagen Biomedical Inc.
    Inventors: Kai Fan, Zhiquan Zhao, Yong Chen, Chun Zhang, Lin Wang
  • Patent number: 8546525
    Abstract: The invention relates to a nucleic acid molecule selected from the group comprising a) a nucleic acid molecule having one of the nucleotide sequences presented in SEQ ID:NO 4 to SEQ ID:NO 8, b) a nucleic acid molecule that codes for a peptide having one of the amino acid sequences presented in SEQ ID:NO 12 to SEQ ID:NO 16, c) a nucleic acid molecule, the complementary strand of which hybridizes to a nucleic acid molecule according to a) or b) and which codes for a peptide having antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which deviates from the nucleotide sequence of a nucleic acid molecule according to c) because of the degenerated genetic code.
    Type: Grant
    Filed: November 20, 2010
    Date of Patent: October 1, 2013
    Assignee: Christian-Albrechts-Universität zu Kiel
    Inventor: Joachim Grötzinger
  • Patent number: 8529890
    Abstract: Provided are improvements in and relating to pharmaceutical compositions for oral administration of polymeric biological drug substances and to methods of treatment using such compositions. In particular, an oral and/or mucosal pharmaceutical composition is provided, said composition comprising an enteric-coated drug substance, and also comprising an enteric-coated oligouronate, wherein said drug substance is a polymeric biological drug substance.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: September 10, 2013
    Assignee: NTNU Technology Transfer AS
    Inventors: Kurt Ingar Draget, Catherine Taylor
  • Patent number: 8492517
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: July 23, 2013
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 8481482
    Abstract: Methods of using portions of the N-terminal domain of prion protein for binding hemin are disclosed. In a particular embodiment, a method comprises administering at least one isolated amino acid sequence comprising a peptide from the octarepeat region of PrPC to a solution containing hemin, wherein the isolated amino acid sequence is effective for forming one or more chemical bonds with hemin.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: July 9, 2013
    Assignee: The Florida State University Research Foundation, Inc.
    Inventor: Ewa Bienkiewicz
  • Patent number: 7803396
    Abstract: A product controlling dissolving rate of biomedical orthopedic implant material and a process of manufacturing the same are disclosed. At constant temperature and humidity and under vacuum, treatment solution is forced to diffuse to the material to form a second phase as a means of controlling the dissolving rate. Different treatment solution can form the phases having different structures from that of matrix. The inventive product has a structure of laminate concentric circle. The second phase and the structure of laminate concentric circle are used as ways for medicine release.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: September 28, 2010
    Inventor: Chin-Chi Yeh
  • Patent number: 7763279
    Abstract: A process for the production of CS particles (10) and microcapsules (12) is described, in which at least one active compound (4) is adsorbed in porous templates (2) (A), as a result of which templates (5) filled with active compounds are present. Subsequently, the templates (2) are provided (B) with a primer layer (6) which is intended to facilitate the subsequent construction of the capsule shell (9). The capsule shell is formed (C) by applying alternately charged polyelectrolyte layers (8). Filled CS particles (10) are obtained. By subsequent dissolution of the templates (2) the active compounds (4) are released (D) from the template into the interior of the microcapsules. The active compounds (4) remain enclosed there or are slowly released (E) from the capsule.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: July 27, 2010
    Assignee: Capsulution Pharma AG
    Inventors: Lars Dahne, Barbara Baude
  • Patent number: 7759368
    Abstract: A sustained release composition for oral administration of niacin, comprising niacin; a carrier for sustained release composed of a hydrophilic polymer and a hydrophobic polymer; and a pharmaceutically acceptable additive, the hydrophilic polymer being a polyethylene oxide and a natural gum, is capable of maintaining a constant release rate of niacin.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: July 20, 2010
    Assignee: Hanmi Pharm. Co., Ltd
    Inventors: Jong Soo Woo, Young Hun Kim
  • Patent number: 7723387
    Abstract: A dermatologic peel comprising alpha hydroxyl acid and metal hydroxide nanocomplexes as neutralizing agents to continually reduce the activity of the system when the acid and neutralizer components are mixed. For example, a 30% glycolic acid gel mixed with a fluidized magaldrate neutralizer can be applied to the skin and will self-neutralize to a skin-compatible pH within a few minutes, effectively exfoliating the skin without a separate neutralization step. The peel is advantageously applied from a two-component system that mixes the components.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: May 25, 2010
    Assignee: Polymer Surfaces Group, LLC
    Inventors: Robert MacDonald Smith, Otto William Wendel, Archie McBride
  • Patent number: 7718677
    Abstract: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: May 18, 2010
    Assignee: Parkinson's Institute
    Inventors: Maryka Quik, Donato Di Monte, J. William Langston
  • Patent number: 7691400
    Abstract: A medical device having a drug-eluting coating that includes a pharmaceutical compound or, more generally, a therapeutic material housed within pores of a zeolite carrier. The zeolite carrier has an open porous structure with reservoirs for holding the therapeutic material. The therapeutic material loaded zeolites may be suspended or dispersed within a bioerodible polymer matrix to provide controlled delivery of the therapeutic material. Zeolite drug carriers may have enhanced or optimally engineered pore sizes for a particular therapeutic material and release profile. Along with a therapeutic material, reservoirs of a zeolite drug delivery system may include a release agent. The release agent may be used to entrap the therapeutic material until such time as a triggering condition is met that prompts the release agent to activate and thereby release the therapeutic material from the zeolite reservoir.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: April 6, 2010
    Assignee: Medtronic Vascular, Inc.
    Inventor: Richard Francis
  • Patent number: 7229959
    Abstract: This invention provides supplemented and unsupplemented tissue sealants as well as methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one antibody. The composition may be further supplemented with, for example, one or more analgesics, antimicrobial compositions, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 12, 2007
    Assignee: The American National Red Cross
    Inventors: William N. Drohan, Martin J. MacPhee, Hernan Nunez, Gene Liau, Wilson H. Burgess, Thomas Maciag
  • Patent number: 7217294
    Abstract: An acellular matrix implant for treatment of defects and injuries of articular cartilage, bone or osteochondral bone and a method for treatment of injured, damaged, diseased or aged articular cartilage or bone, using the acellular matrix implant implanted into a joint cartilage lesion in situ and a bone-inducing composition implanted into an osteochondral or bone defect. A method for repair and restoration of the injured, damaged, diseased or aged cartilage or bone into its full functionality by implanting the acellular matrix implant between two layers of biologically acceptable sealants and/or the bone-inducing composition into the osteochondral bone or skeletal bone defect. A method for fabrication of the acellular matrix implant of the invention. A method for preparation of bone-inducing composition.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: May 15, 2007
    Assignee: Histogenics Corp.
    Inventors: Akihiko Kusanagi, Laurence J. B. Tarrant, Mary Beth Schmidt
  • Patent number: RE39585
    Abstract: This invention provides materials and procedures for the delivery of selected strains of bacteria and/or oxalate-degrading enzymes to the intestinal tracts of persons who are at increased risk for oxalate related disease because they have lost, or have inadequate concentrations of these bacteria. The administration of these bacteria and/or the relevant enzyme removes oxalate from the intestinal tract and thus reduces the amount of oxalate available for absorption and reduces the risk for oxalate related disease.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: April 24, 2007
    Assignee: VSL Pharmaceuticals, Inc.
    Inventor: Claudio DeSimone